Quantitative detection of inhaled formoterol in human urine and relevance to doping control analysis

Drug Testing and Analysis

Volumn 4, Issue 6, 2012, Pages 449-454

  Deventer, K ^a   Pozo, O J ^b   Delbeke, F T ^a   Van Eenoo, P ^a  

^a GHENT UNIVERSITY   (Belgium)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

Detection; Doping; Formoterol; LC MS; Urine

Indexed keywords

BODY FLUIDS; DRUG DOSAGE; DRUG PRODUCTS; ELECTROSPRAY IONIZATION; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHYSIOLOGY;

DETECTION; DOPING CONTROL ANALYSIS; FORMOTEROL; HUMAN URINE; LC-MS; QUANTITATIVE DETECTION; THERAPEUTIC USE; URINARY EXCRETION; URINE; URINE SAMPLE;

ENZYMATIC HYDROLYSIS;

FORMOTEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DOPING; DRUG CONJUGATION; DRUG CONTROL; DRUG URINE LEVEL; ELECTROSPRAY; HUMAN; HYDROLYSIS; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; URINARY EXCRETION; URINE PH;

EID: 84863096913     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.418     Document Type: Article

References (22)

1. D. Faulds, L. M. Hollingshead, K. L. Goa. Formoterol - A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991, 42, 115.
2. A. Polettini. Bioanalysis of beta 2-agonists by hyphenated chromatographic and mass spectrometric techniques. J. Chromatogr. B 1996, 687, 27.
3. World Anti-Doping Agency (WADA). The 2011 Prohibited List, International Standard, 2011. Available at: [1 September 2011].
4. World Anti-Doping Agency (WADA). Technical document: Minimum Required Performance Limits for Detection of Prohibited Substances: TD2010MRPL, 2010. Available at:. [13 January 2011].
5. R. Ventura, L. Damasceno, M. Farre, J. Cardoso, J. Segura. Analytical methodology for the detection of beta(2)-agonists in urine by gas chromatography-mass spectrometry for application in doping control. Anal. Chim. Acta 2000, 418, 79.
6. L. Damasceno, R. Ventura, J. Ortuno, J. Segura. Derivatization procedures for the detection of beta(2)-agonists by gas chromatographic/mass spectrometric analysis. J. Mass Spectrom. 2000, 35, 1285.
7. M. Thevis, G. Opfermann, W. Schanzer. Liquid chromatography/electrospray ionization tandem mass spectrometric screening and confirmation methods for beta(2)-agonists in human or equine urine. J. Mass Spectrom. 2003, 38, 1197.
8. K. Deventer, O. J. Pozo, F. T. Delbeke, P. Van Eenoo. Quantitative detection of inhaled salmeterol in human urine and relevance to doping control analysis. Ther. Drug Monit. 2011, 33, 627.
9. R. Ventura, R. Ramirez, N. Monfort, J. Segura. Ultraperformance liquid chromatography tandem mass spectrometric method for direct quantification of salbutamol in urine samples in doping control. J. Pharm. Biomed. Anal. 2009, 50, 886.
10. M. J. Kang, Y. H. Hwang, W. Lee, D. H. Kim. Validation and application of a screening method for beta 2-agonists, anti-estrogenic substances and mesocarb in human urine using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21, 252.
11. W. Van Thuyne, F. T. Delbeke. Declared use of medication in sports. Clin. J. Sport Med. 2008, 18, 143.
12. W. Verwaal, M. van Bavel, A. Boot, J. Bravenboer, F. de Goei, C. Maas, et al. Valideren van (fysisch-) chemische en (fysisch-) mechanische methoden op het niveau van de wettelijke eis. De ware(n)-chemicus 1996, 26, 1.
13. F. Bressolle, M. BrometPetit, M. Audran. Validation of liquid chromatographic and gas chromatographic methods - Applications to pharmacokinetics. J. Chromatogr. B 1996, 686, 3.
14. M. K. Henze, G. Opfermann, W. Schänzer. Liquid-liquid extraction pH-profiles of selected beta-2-sympathomimetic agonists, in Recent Advances in Doping Analysis (7), Proceedings of the 17th Cologne Workshop on dope analysis, (Eds: W. Schänzer, H. Geyer, A. Gotzmann, U. Mareck-Engelke), Sport & Buch Strauss, Cologne, Germany, 1999, pp. 335.
15. D. J. Morgan. Clinical Pharmacokinetics of Beta-Agonists. Clin. Pharmacokinet. 1990, 18, 270.
16. M. Zhang, J. P. Fawcett, J. P. Shaw. Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. Br. J. Clin. Pharmacol. 2002, 54, 246.
17. J. Rosenborg, P. Larsson, K. Tegner, G. Hallstrom. Mass balance and metabolism of [H-3]formoterol in healthy men after combined IV and oral administration-mimicking inhalation. Drug Metab. Dispos. 1999, 27, 1104.
18. H. Kamimura, H. Sasaki, S. Higuchi, Y. Shiobara. Quantitative-determination of the beta-adrenoceptor stimulant formoterol in urine by gas-chromatography mass-spectrometry. J. Chrom. 1982, 229, 337.
19. J. B. Lecaillon, G. Kaiser, M. Palmisano, J. Morgan, G. Della Cioppa, A. Piriano. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of foradil dry powder inhalation via Aerolizer (TM). Eur. J. Clin. Pharmacol. 1999, 55, 131.
20. G. R. Wilkinso, A. H. Beckett. Absorption Metabolism and Excretion of Ephedrines in Man. I. Influence of Urinary Ph and Urine Volume Output. J. Pharmacol. Exp. Ther. 1968, 162, 139.
21. A. Ryrfeldt, P. Andersson, S. Edsbacker, M. Tonnesson, D. Davies, R. Pauwels. Pharmacokinetics and Metabolism of Budesonide, a Selective Glucocorticoid. Eur. J. Resp. Dis. 1982, 63, 86.
22. Patient Information Leaflet Oxis Turbohaler (July 2004). Astra Zeneca (2004). Available at: [4 October 2011].